OBSCN and prostate carcinoma: Loss or mutation of OBSCN has been implicated in: brain tumors, oral squamous cell carcinoma, gastrointestinal tract cancers, Wilms tumor, renal cell carcinoma, female reproductive cancers (ovarian, endometrial), prostate cancer, breast cancer and melanoma.